Language:EnglishEspañolPortuguês BR中文Bahasa Melayu
Terms of Use visual
Buyer-focused senolytic research

Terms of Use

Take the ReCellence Cellular Assessment

Content is provided for general educational and consumer-research purposes. No content forms a clinician-patient relationship or guarantees product results. Product information can change; verify current labels, prices and warnings with the seller before purchase.

Last updated: August 10, 2026.

Research references

Health disclaimer: Senolytic research is an emerging field. Much fisetin evidence is preclinical, and human evidence remains limited. This page is educational and is not medical advice. Ask a qualified healthcare professional before using supplements, especially if you have a medical condition, are pregnant, or take medication.

Educational use

SenolyticReport provides consumer research and educational information. It does not create a medical relationship and does not replace individualized professional advice.

Changing product information

Formulas, prices, testing documents, serving sizes, certifications, and product availability can change. Readers should verify current manufacturer information before purchase.

No guaranteed outcomes

No score, article, comparison, or product listing guarantees senolysis, age reversal, disease prevention, or another health outcome.

Third-party links

Manufacturers, marketplaces, and research databases control their own content, transactions, privacy practices, and fulfillment.

Original content and data

Original text, scoring systems, and structured databases should not be republished wholesale without permission, subject to applicable legal exceptions.

Acceptable use

Users should not interfere with site operation, attempt unauthorized access, or use the site to distribute malicious or unlawful content.

Commercial relationships

Commercial links do not create a warranty about a manufacturer or product.

Changes to terms

Terms may change as site functions change. The current published version governs current use subject to applicable law.

Update trigger 1

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 2

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 3

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 4

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 5

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 6

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 7

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 8

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 9

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 10

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 11

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 12

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 13

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 14

For Terms of Use, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.